Medical supply and sovereignty in Morocco: the limits of public–private partnerships
The Promamec–Ansell partnership illustrates the benefits and limits of distribution agreements in Morocco, from supply security to local production and technology transfer.
Imports still meet 85–90% of national demand for medical devices (LesEco, Medical Device Day) as the expansion of compulsory health insurance (AMO) and hospital infrastructure structurally increase consumption volumes. The gap between growing demand and local production concentrated in low-value-added segments is generally presented as the main vulnerability in Morocco’s health supply chain—a characterisation that reflects a public policy choice as much as a technical assessment.
The signing in June 2026 of a distribution partnership between Moroccan operator Promamec and Australian manufacturer Ansell (Morocco World News) illustrates the use of the private sector to widen access to equipment meeting international standards. This brief examines the scope and limits of such agreements. It argues that public–private partnerships provide a starting point, not a solution in themselves: their effect on supply security depends on the regulatory framework, technology-transfer requirements and arrangements for securing public procurement that govern them.
Strategic context
Import dependence can be understood in terms of systemic resilience as well as trade balance. It is not inherently a failure—external sourcing may reflect comparative advantage—but it exposes the system to interruption risks. That, rather than an economic anomaly, explains public authorities’ interest. Figures presented at Medical Device Day indicate that imports meet 85–90% of national demand, with Morocco sourcing mainly from Germany, China and the United States. This configuration exposes the health system to logistical and geopolitical risks whose scale the 2020 health crisis revealed.
The market structure clarifies these constraints. The sector generated turnover of around MAD 7 billion and approximately 4,000 jobs in 2024, according to figures provided by the employers’ organisation CGEM through Maroc.ma. Local manufacturing indicators remain modest: around 1,378 jobs and MAD 903 million in turnover, with a value-added rate of 46%. Domestic manufacturing concentrates on low-value-added products—dressings, syringes and gloves—while imaging equipment and orthopaedic or dental devices remain largely imported.
Public authorities have launched a structured response. A 2026–2030 framework agreement, signed alongside the second Medical Device Day by the Ministry of Health and Social Protection, the Ministry of Industry and Trade, the Moroccan Agency for Medicines and Health Products (AMMPS), CGEM and the Moroccan Federation of Health Industries (FMIS), sets objectives for import substitution, supply-chain security and local manufacturing. Industry Minister Ryad Mezzour and Health Minister Amine Tehraoui linked the initiative to the doctrine of health sovereignty articulated after the pandemic.
The 2020 crisis also revealed latent industrial capacity: faced with a global mask shortage, Morocco moved from a deficit to exporting around half its local production (Aujourd’hui Le Maroc). The country now has more than 200 industrial units producing medical devices (Le360), and the sector strategy envisages Morocco as a regional hub serving African markets. This responsiveness in a crisis has not translated into a lasting reduction in dependence under normal conditions: the issue therefore shifts from industrial potential to the conditions needed to sustain it.
Case analysis: the Promamec–Ansell partnership
The agreement was formalised in Casablanca in the presence of public and private partners. Under its terms, Promamec distributes surgical and examination gloves in Morocco for Ansell, a manufacturer founded in Australia in 1893 (Le Nouvelliste). Promamec CEO Naoufal Lahlou described the operation as a development milestone, while Ekaterina Bogomolova, Vice-President of Ansell’s medical business for EMEA and ANZ, placed it within the group’s African expansion strategy. These assessments come from parties to the agreement and therefore form part of their communications.
Several features give the case analytical value. Founded in 1981 and among the three dominant operators in Morocco’s market (Aujourd’hui Le Maroc), Promamec has a local consumables production unit. Its chief executive also chairs FMIS, placing the agreement at the intersection of corporate strategy and sector policy—a configuration that calls for caution in interpreting public positions. The operation improves public and private facilities’ access to standard-compliant products and strengthens national distribution capacity.
These benefits should be assessed neutrally. The agreement concerns distribution, not the transfer of production: it does not itself increase local integration. The products involved belong to low-value-added segments that Moroccan manufacturing already partly supplies. It therefore does not change structural dependence on sophisticated equipment, the core of the identified vulnerability. As it stands, the partnership secures an access channel and a level of quality; it does not change the supply architecture.
Policy pillars and recommendations
1. Use public procurement as a lever for local integration
Public procurement accounts for a decisive share of the medical devices market (Oxford Business Group, with tenders representing 60–70% of turnover). Making part of this demand conditional on local-content and quality criteria would provide domestic producers with a predictable market. The FMIS president advocates securing public procurement for domestic production, but this remains the position of a directly interested actor. Such a mechanism also has costs: local-content preferences tend to raise procurement costs and may create rents or weaken competition on quality, making rigorous targeting and evaluation essential.
2. Distinguish distribution agreements from technology transfer
International partnerships advance sovereignty only when they include manufacturing, licensing or know-how transfer. The 2026–2030 framework agreement explicitly encourages such industrial partnerships. Incentives should favour agreements committing to local production over distribution-only arrangements, increasing the value added retained domestically. There are trade-offs: localisation requirements may deter some foreign partners or raise prices, and compulsory localisation policies have a mixed international record.
3. Stabilise regulation and authorisation timelines
The absence of a one-stop shop and reportedly lengthy market-authorisation procedures slow the expansion of local production (Challenge). Consolidating AMMPS’s role and simplifying procedures are prerequisites for the regulatory clarity industrial investment requires. Simplification must not weaken vigilance: faster authorisations need to be reconciled with the safety and medical-device vigilance requirements that AMMPS safeguards.
4. Strengthen technical and regulatory skills
The framework agreement identifies workforce training as a central component. The availability of qualified technical and regulatory staff determines local industry’s ability to meet international standards; it is a prerequisite for increasing local content, not an optional addition. This effort nevertheless competes for scarce resources with other health priorities, and qualified staff may be drawn into the private sector or export activities rather than the intended upgrading of domestic production.
Limitations and objections
Three qualifications frame the analysis. First, it treats reduced import dependence as desirable. This premise is debatable: economic theory recognises that imports may reflect comparative advantage and that health sovereignty is a public policy choice carrying costs, not an intrinsic good. Second, much of the evidence comes from interested actors—employers’ organisations, the industry federation and domestic business media—without independent evaluation; turnover, employment and dependence figures must be read accordingly. Finally, the recommended levers carry their own costs—higher procurement expenditure, capture risks and trade-offs between regulatory speed and safety—which a neutral assessment weighs against expected resilience benefits.
Institutional challenges and conclusion
The trajectory depends on familiar institutional variables: coordination between the health and industry ministries and customs authorities, regulatory stability, access to finance and skills development (L’Opinion / lodj.ma). Without them, industrial ambition encounters the structural delays observed in other sectors.
Funding industrial upgrading is often underestimated. The framework agreement provides for public investment and export-support programmes to assist businesses seeking to manufacture locally (Aujourd’hui Le Maroc). Their effect will depend on effective access for mid-sized operators and coordination with predictable public procurement. Without visibility over future sales, incentives for productive investment remain weak, regardless of the number of distribution agreements signed. This brings the analysis back to the complementary, rather than interchangeable, nature of the different levers.
Industrial and institutional partners—domestic operators, international manufacturers, professional federations and public agencies—are best analysed as components of a public–private ecosystem rather than protagonists of commercial announcements. From this perspective, a distribution agreement, a framework agreement and an FMIS commitment address the same question: how much value, know-how and decision-making are anchored locally? The frequently promoted ambition to export to African markets has strategic meaning only when supported by a consolidated domestic production base.
Public–private partnerships such as Promamec–Ansell can be understood as ecosystem dynamics: they improve access and quality without, by themselves, shifting the boundaries of dependence. For those pursuing sovereignty, the relevant indicator is not the number of agreements signed but changes in local integration and the share of high-value-added production. The effectiveness of the 2026–2030 framework agreement should be measured against these outcomes, while accounting for the costs outlined above.